The recent headlines proclaiming a cure for a Mississippi baby who had been exposed to the HIV virus which causes AIDS have captivated the world. This child was born to an HIV positive mother who had not received any prenatal care to reduce the transmission of the virus. Dr. Hannah Gay, who treated the baby,[…]
Can Ritonavir Boosted Fosamprenavir Lead to a Cure for AIDS?
Anti-Retroviral / Anti-HIV, Drug Research & Development API, Patent Expiration 2017 Tags: AIDSHIV virusNorvirRitonavir Mar 07, 2013
Atazanavir Sulfate Gets a Nod at the 6th International AIDS Society Conference
Anti-Retroviral / Anti-HIV, Antiviral, Drug Research & Development API, Patent Expiration 2017 Tags: antiretroviralHIVNorvirRitonavir Jan 20, 2013
Atazanavir Sulfate, CAS No: 229975-97-7 is also known as the antiretroviral medication Reyataz. With the patent for Reyataz expiring on June 20, 2017 research and development teams are currently working on the development of a generic version of this vital drug. Indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection, atazanavir[…]
Life Extending Enfuvirtide Looks to Become a Successful Generic
Anti-Retroviral / Anti-HIV, Patent Expiration 2013, Patent Expiration 2015 Tags: AIDSHIVHIV infectionRitonavir Jun 27, 2012
In June of 1981 the first known cases of AIDS in the United States were reported. Currently there are over 1.7 million people in the United States infected with HIV-1, the virus which causes AIDS, and over more then 600,000 Americans have already died from this ultimately fatal disease. With 1.2 million Americans estimated to[…]
Ritonavir Boosts the Efficacy of Protease Inhibitors
Anti-Retroviral / Anti-HIV, Drug Research & Development API Tags: HIV infectionNorvirRitonavir May 18, 2012
Ritonavir is also known by it’s brand name Norvir. Marketed by Abbott Laboratories, Norvir will lose it’s patent on January 28, 2014. The patent for the pediatric exclusivity for ritonavir will also expire on July 28, 2014. With the generic possibilities coming near, researchers are clamoring to commence clinical trials of ritonavir. As an antiviral[…]
Darunavir Ethanolate continues to Prove it's Viability for HIV Treatment
Anti-Retroviral / Anti-HIV, Antiviral, Drug Research & Development API Tags: antiretroviralDarunavir EthanolateHIV infectionRitonavir Apr 23, 2012
Darunavir Ethanolate is also known by it’s brand name Prezista, and is used to treat HIV infection. In the class of protease inhibitors, darunavir ethanolate was approved by the FDA in June of 2006. What makes darunavir ethanolate unique is it’s ability to combat drug resistant strains of HIV in affected patients, as well as[…]
Atazanavir Sulfate Essential Treatment for HIV Infected Patients
Anti-Retroviral / Anti-HIV, Drug Research & Development API Tags: antiretroviralHIVRitonavir Feb 27, 2012
Atazanavir Sulfate, CAS# 229975-97-7, is essential in the management of HIV in affected patients. As an inhibitor of the HIV-1 protease, it is often used in combination with other antiretroviral medications to treat HIV-1 infected patients. LGM Pharma is a provider of the API for research and development. With a trade name Reyataz (Bristol-Myers Squibb),[…]
Monotherapy with Darunavir is Where the "MONET" is
Anti-Retroviral / Anti-HIV, Drug Research & Development API Tags: AIDSDarunavir EthanolateHIVHIV virusRitonavir Sep 02, 2011
AIDS is a global pandemic whose cure has eluded scientists and doctors for more than 2 decades. Acquired immunodeficiency syndrome (AIDS) is caused by the Human Immunodeficiency Virus (HIV) which progressively undermines the strength of the immune system until such a time that the body becomes incapable of fighting off infections and vulnerable to opportunistic[…]
